Title:Efficacy of Chemoimmunotherapy versus Chemotherapy for Gastric
Cancer: A Meta-Analysis of Survival Outcomes
Volume: 31
Issue: 18
Author(s): Juan Xie, Lin Chen, Qing Liu, Xi-Tai Li and Xiao-Yong Lei*
Affiliation:
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan,
421001, China
- Hunan Provincial Key Laboratory of Tumor Microenvironment
Responsive Drug Research, University of South China, Hengyang, Hunan, 421001, China
Keywords:
Gastric cancer, chemotherapy, immunotherapy, overall survival, disease-free survival, dendritic cell.
Abstract:
Background: Gastric cancer has been traditionally treated with chemotherapy
as the primary mode of treatment. However, recent studies have shown that chemoimmunotherapy
is also effective and, in some cases, better than chemotherapy treatment.
Current study aimed to find the efficacy of chemoimmunotherapy versus chemotherapy
in the treatment of gastric cancer.
Methods: Using electronic databases, including PubMed, Embase, and EBSCO, a thorough
literature search was carried out for the years 2006 to 2023. The search strategy
was designed to identify relevant studies based on chemoimmunotherapy and chemotherapy
intervention, and the search was conducted using appropriate keywords and MeSH
terms. The retrieved studies were screened for relevance based on their titles, abstracts,
and full texts. The studies' inclusion criteria were predefined, and the selected studies
were then subjected to a quality assessment using GradePro GDT. The data from selected
studies were extracted and analyzed using Revman version 5.4.
Results: The study found that chemoimmunotherapy treatment resulted in a significant
improvement in overall survival (OS) with a risk ratio (RR) of 1.54 and a 95% Confidence
Interval (CI) of 1.25 to 1.89. The overall effect was also found to be significant,
with a p-value of less than 0.001. Furthermore, we also observed an improvement in the
1-year, 3-year, and 5-year survival rates with risk ratio (RR) of 1.09 (95% CI: 1.01,
1.17), 1.43 (95% CI: 1.28, 1.60), and 1.59 (95% CI: 1.10, 2.30), respectively. In addition,
it’s also found that chemoimmunotherapy treatment also resulted in an improvement
in DFS with an RR of 1.94 and a 95% CI of 1.44 to 2.59. Overall, these results
suggest that chemoimmunotherapy treatment can be an effective approach in comparison
to chemotherapy for improving overall survival and disease-free survival in the
studied population.
Conclusion: This study comparing chemoimmunotherapy versus chemotherapy for gastric
cancer showed that both treatments were effective, but chemoimmunotherapy had
more significant efficacy. To support these results, additional studies with a large sample
size and a longer follow-up time are required.
